The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Increase in insulin action and fat oxidation after treatment with CL 316,243, a highly selective beta3-adrenoceptor agonist in humans.
Abstract
Stimulation of beta3-adrenoceptors by selective agonists improves insulin action and stimulates energy metabolism in various rodent models of obesity and type 2 diabetes. Whether selective beta3-adrenoceptor stimulation exerts metabolic actions in humans remains to be proven. The effects of a highly selective beta3-adrenoceptor agonist on insulin action, energy metabolism, and body composition were assessed in 14 healthy young lean male volunteers (age 22.5 +/- 3.3 years, 15 +/- 5% body fat [mean +/- SD]) randomly assigned to 8 weeks of treatment with either 1,500 mg/day of CL 316,243 (n = 10) or placebo (n = 4). Insulin-mediated glucose disposal (IMGD), nonoxidative glucose disposal (NOGD), oxidative glucose disposal (OGD) (indirect calorimetry), and splanchnic glucose output (SGO; beta3-[H3]glucose) were determined during a 100-min hyperinsulinemic-euglycemic glucose clamp (40 mU x m(-2) x min(-1)) before and after 4 and 8 weeks of treatment. The 24-h energy expenditure (24-EE), 24-h respiratory quotient (24-RQ), and the oxidation rates of fat and carbohydrate were determined in a respiratory chamber before and after 8 weeks. After 4 weeks, treatment with CL 316,243 increased IMGD (+45%, P < 0.01) in a plasma concentration-dependent manner (r = 0.76, P < 0.02). This effect was due to an 82% increase in NOGD (P < 0.01), while OGD and SGO remained unchanged. The effects on insulin action were markedly diminished after 8 weeks; this was significantly related to an unexpected decline in the plasma concentrations of CL 316,243 (-36%, P = 0.08). At this time, 24-RQ was lowered (P < 0.001), corresponding to a 23% increase in fat oxidation (P < 0.01) and a 17% decrease in carbohydrate oxidation (P = 0.05). The 24-EE after 8 weeks did not differ from baseline, and there was no change in body weight or body composition. Plasma concentrations of glucose, insulin, and leptin were unaffected by treatment, while free fatty acid concentrations increased by 41% (P < 0.05), again linearly with the achieved plasma concentration of CL 316,243 (r = 0.67, P < 0.05). Treatment with CL 316,243 had no effect on heart rate or blood pressure and caused no cases of tremors. We conclude that treatment of lean male subjects with CL 316,243 increases insulin action and fat oxidation, both in a plasma concentration-dependent manner. This is the first study to demonstrate unequivocal metabolic effects of a highly selective beta3-adrenoceptor agonist in humans.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Histological evidence has indicated that brown fat is present, albeit in small amounts, in adults, throughout life 76, but attempts to find functional BAT 77 or utilize its thermogenesis for weight loss 78,79 have been largely unsuccessful.”
From Cellular bioenergetics as a target for obesity therapy (2010) · cites this paper as [78]
Citations
Cites
INFLUENCES OF GLUCOSE LOADING AND OF INJECTED INSULIN ON HEPATIC GLUCOSE OUTPUT*
Steele, R. D. (1959) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1959.tb44923.x · Cited by 1,680
Gong, D., He, Y., Karas, M., & Reitman, M. L. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.39.24129 · Cited by 740
Mantzoros, C. S., Frederich, R. C., Flier, J. S., Qu, D., Susulic, V. S., Lowell, B. B., & Maratos–Flier, E. (1996) · Diabetes · doi:10.2337/diab.45.7.909 · Cited by 314
Yoshida, T., Sakane, N., Wakabayashi, Y., Umekawa, T., & Kondo, M. (1994) · Life Sciences · doi:10.1016/0024-3205(94)00408-0 · Cited by 107
de Souza, C. J., Hirshman, M. F., & Horton, E. S. (1997) · Diabetes · doi:10.2337/diab.46.8.1257 · Cited by 95
Thermogenic and antiobesity activity of a novel β-adrenoceptor agonist (BRL 26830A) in mice and rats
Arch, J., & Ainsworth, A. T. (1983) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/38.4.549 · Cited by 74
Acheson, K. J., Ravussin, É., Schoeller, D. A., Christin, L., Bourquin, L. D., Baertschi, P., Danforth, E., & Jéquier, E. (1988) · Metabolism · doi:10.1016/0026-0495(88)90035-2 · Cited by 65
Self-citationLack of beta 3-adrenergic effect on lipolysis in human subcutaneous adipose tissue
ROSENBAUM, M. S., Malbon, C. C., Hirsch, J., & Leibel, R. L. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.77.2.8393882 · Cited by 63
Treatment of obesity with thermogenic beta-adrenoceptor agonists: studies on BRL 26830A in rodents.
Arch, J. R. S., Ainsworth, A. T., Ellis, R. D., Piercy, V., Thody, V. E., Thurlby, P. L., Wilson, C., Wilson, S., & Young, P. (1984) · PubMed · Cited by 63
Antidiabetic and antiobesity effects of a highly selective β3‐adrenoceptor agonist (CL 316,243)
Largis, E. E., Burns, M. G., Muenkel, H. A., Dolan, J. A., & Claus, T. H. (1994) · Drug Development Research · doi:10.1002/ddr.430320203 · Cited by 45
Cited by
Sorted by citations
Obesity and insulin resistance
Kahn, B. B., & Flier, J. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10842 · Cited by 3,345
Activation of Human Brown Adipose Tissue by a β3-Adrenergic Receptor Agonist
Cypess, A. M., Weiner, L. S., Roberts‐Toler, C., Franquet, E., Kessler, S., Kahn, P. A., English, J., Chatman, K., Trauger, S. A., Doria, A., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2014.12.009 · Cited by 1,053
Mice overexpressing human uncoupling protein-3 in skeletal muscle are hyperphagic and lean
Clapham, J. C., Arch, J. R. S., Chapman, H., Haynes, A., Lister, C., Moore, G. B. T., Piercy, V., Carter, S. A., Lehner, I., Smith, S. A., et al. (2000) · Nature · doi:10.1038/35019082 · Cited by 604
Cellular bioenergetics as a target for obesity therapy
Tseng, Y.-H., Cypess, A. M., & Kahn, C. R. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3138 · Cited by 591
New insights into sympathetic regulation of glucose and fat metabolism
Nonogaki, K. (2000) · Diabetologia · doi:10.1007/s001250051341 · Cited by 589
Metadata
- Authors
- Weyer, C., Tataranni, P. A., Snitker, S., Danforth, E., & Ravussin, E.
- Affiliations
- National Institutes of Health (US)
- Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona 85016, USA. cweyer@phx.niddk.nih.gov
- ORCID
- Snitker, S
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 1998-10-01
- Volume
- 47
- Issue
- 10
- Pages
- 1555-1561
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2090592868
- Cited by
- 188
- References
- 13
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 2 · 2023: 7 · 2022: 8 · 2021: 8 · 2020: 6 · 2019: 9 · 2018: 8 · 2017: 9 · 2016: 12 · 2015: 12 · 2014: 6 · 2013: 4 · 2012: 5
- FWCI
- 7.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- CL316,243, beta3-adrenergic agonists, insulin action, insulin-stimulated glucose disposal, nonoxidative glucose disposal, fat oxidation, carbohydrate oxidation, respiratory quotient, energy expenditure, body composition, plasma drug concentration, type 2 diabetes, obesity, energy metabolism
- MeSH terms
- Adrenergic beta-Agonists, Adult, Blood Glucose, Body Composition, Body Weight, Dioxoles, Double-Blind Method, Energy Metabolism, Fatty Acids, Nonesterified, Humans, Insulin, Male, Oxidation-Reduction, Proteins, Glucose Clamp Technique, Leptin, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
